文献速递眼底病与葡萄膜炎

欧洲MYO7A患者多中心纵向前瞻性研究:疾病病程及对基因治疗的启示

Multicentric Longitudinal Prospective Study in a European Cohort of MYO7A Patients: Disease Course and Implications for Gene Therapy.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2024-01-01

这项欧洲多中心前瞻性纵向研究纳入53例MYO7A双等位基因变异所致Usher综合征患者,基线及两次年度随访评估视网膜营养不良自然病史。纵向分析(50例)显示较好眼BCVA显著下降,而较差眼各参数无变化;眼底自发荧光模式与视网膜损伤分期相关,作者倡导将其作为未来基因治疗临床试验患者筛选的客观生物标志物。

要点

  • 基线时所有患者BCVA、半自动动态视野及黄斑敏感度均下降,SD-OCT示中心黄斑厚度降低、椭圆体带宽度变窄。
  • 纵向分析(50例)示较好眼BCVA显著下降,较差眼各参数无变化。
  • 高自发荧光黄斑斑块(16眼,31.4%)和异常中心低自发荧光(9眼,17.6%)与更差的形态和功能指标显著相关。

核心结论

  • 该欧洲多中心研究提供了迄今最大MYO7A患者队列之一的首个前瞻性纵向分析,证实疾病进展缓慢。
  • 研究强调眼底自发荧光模式在视网膜损伤分期中的关键作用,并倡导将其作为未来基因治疗临床试验患者筛选的客观生物标志物。

研究设计与样本

  • 多中心纵向前瞻性研究,纳入53例MYO7A双等位基因(多为致病性)变异所致Usher综合征患者,平均年龄33.6±16.7岁,接受基线和两次年度随访。
  • 评估包括最佳矫正视力(BCVA)、半自动动态视野、全视野视网膜电图、彩色眼底成像、微视野、谱域光学相干断层扫描(SD-OCT)和眼底自发荧光。

主要发现

  • 基线时较好眼和较差眼BCVA分别为66.4±17.9和59.5±21.7 Early Treatment Diabetic Retinopathy评分。
  • 基线时较好眼和较差眼半自动动态视野III4e面积分别为3365.8±4142.1°2和4176.4±4400.3°2,黄斑敏感度分别为9.7±9.9 dB和9.0±10.2 dB。
  • 基线时SD-OCT示较好眼和较差眼中心黄斑厚度分别为259.6±63.0 µm和250.7±63.3 µm,椭圆体带宽度分别为2807.5±2374.6 µm和2615.5±2370.4 µm。
  • 纵向分析(50例)显示较好眼BCVA显著下降,而较差眼各参数均无变化。
  • 基线时BCVA、半自动动态视野(III4e和V4e)及黄斑敏感度与年龄显著相关。

关键数值与推荐

  • 高自发荧光黄斑斑块(16眼,31.4%)和异常中心低自发荧光(9眼,17.6%)与更差的形态和功能指标显著相关,而高自发荧光环模式为22眼(43.1%)。

临床怎么用

  • 作者倡导将眼底自发荧光模式作为未来基因治疗临床试验患者筛选的客观生物标志物。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We investigated the natural history of retinal dystrophy owing to variants in the MYO7A gene. METHODS: Fifty-three patients (mean age, 33.6 ± 16.7 years) with Usher syndrome owing to biallelic, mostly pathogenic, variants in MYO7A underwent baseline and two annual follow-up visits. Best-corrected visual acuity (BCVA), semiautomatic kinetic visual field, full-field electroretinogram, color fundus imaging, microperimetry, spectral-domain optical coherence tomography, and fundus autofluorescence were assessed. RESULTS: At baseline, all patients presented with decreased BCVA (66.4 ± 17.9 Early Treatment Diabetic Retinopathy score and 59.5 ± 21.7 Early Treatment Diabetic Retinopathy score, in the better- and worse-seeing eyes, respectively), restricted semiautomatic kinetic visual field (III4e area, 3365.8 ± 4142.1°2; 4176.4 ± 4400.3°2) and decreased macular sensitivity (9.7 ± 9.9 dB; 9.0 ± 10.2 dB). Spectral-domain optical coherence tomography revealed reduced central macular thickness (259.6 ± 63.0 µm; 250.7 ± 63.3 µm) and narrowed ellipsoid zone band width (2807.5 ± 2374.6 µm; 2615.5 ± 2370.4 µm). Longitudinal analyses (50 patients) showed a significant decrease of BCVA in better-seeing eyes, whereas no changes were observed in worse-seeing eyes for any parameter. BCVA, semiautomatic kinetic visual field (III4e and V4e) and macular sensitivity were related significantly to age at baseline. Hyperautofluorescent foveal patch (16 eyes [31.4%]) and abnormal central hypoautofluorescence (9 eyes [17.6%]) were significantly associated with worse morphological and functional read-outs compared with the hyperautofluorescent ring pattern (22 eyes [43.1%]). CONCLUSIONS: Our European multicentric study offers the first prospective longitudinal analysis in one of the largest cohorts of MYO7A patients described to date, confirming the slow disease progression. More important, this study emphasizes the key role of fundus autofluorescence patterns in retinal impairment staging and advocates its adoption as an objective biomarker in patient selection for future gene therapy clinical trials.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Testa F, Carreño E, van den Born LI, et al. Multicentric Longitudinal Prospective Study in a European Cohort of MYO7A Patients: Disease Course and Implications for Gene Therapy. Invest Ophthalmol Vis Sci. 2024. PMID: 38884554. doi:10.1167/iovs.65.6.25

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。